SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950123-01-502018
Filing Date
2001-05-08
Accepted
2001-05-08 00:00:00
Documents
1
Period of Report
2000-12-31

Document Format Files

Seq Description Document Type Size
1 NYMOX PHARMACEUTICAL CORPORATION m09817tfe20-f.txt 20-F 246788
  Complete submission text file 0000950123-01-502018.txt   248290
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT, QUEBEC CANADA, H4M 2V2 A8
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT, QUEBEC CANADA H4M 2V2 A8 514-332-3222
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 1625482
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences